OBJECTIVE: To evaluate phenotypic drug susceptibility and non-nucleoside reverse transcriptase inhibitor hypersusceptibility as predictors of the time to virological failure. DESIGN: In a randomized clinical trial, phenotypic susceptibility was retrospectively determined among 131 exclusively nucleoside reverse transcriptase inhibitor (NRTI)-experienced patients with baseline HIV-RNA levels greater than 2000 copies/ml. Subjects were assigned two NRTI drugs and were randomly assigned to nelfinavir, efavirenz, or both. Virological failure was defined as two HIV-RNA measurements of 2000 copies/ml or greater at or after week 16 and before treatment discontinuation. METHODS: Using biological cut-offs to define resistance, assigned NRTI and randomized drug regimens, continuous and dichotomous phenotypic susceptibility scores (PSS) were calculated for each virus. Efavirenz hypersusceptibility as a dichotomous value was defined as less than 0.4-fold resistance. Associations between virological failure and continuous and dichotomous PSS were evaluated using Kaplan-Meier curves and Cox proportional hazards regression models. RESULTS: A higher baseline viral load (P < 0.02) and lower dichotomous or continuous baseline PSS (P = 0.004 and P < 0.001, respectively) were independently associated with virological failure. In the 85 subjects who received efavirenz, efavirenz hypersusceptibility (P = 0.042, hazard ratio 0.43, 95% confidence interval 0.19-0.97) was independently associated with a reduced risk of virological failure. CONCLUSION: Reduced phenotypic susceptibility was a significant independent risk factor for virological failure. The presence of efavirenz hypersusceptibility appeared to enhance virological responses during treatment with efavirenz in combination with NRTIs. The retrospective calculation of continuous PSS accurately identified treatment regimens containing sufficient drug activity to prevent virological failure.
RCT Entities:
OBJECTIVE: To evaluate phenotypic drug susceptibility and non-nucleoside reverse transcriptase inhibitor hypersusceptibility as predictors of the time to virological failure. DESIGN: In a randomized clinical trial, phenotypic susceptibility was retrospectively determined among 131 exclusively nucleoside reverse transcriptase inhibitor (NRTI)-experienced patients with baseline HIV-RNA levels greater than 2000 copies/ml. Subjects were assigned two NRTI drugs and were randomly assigned to nelfinavir, efavirenz, or both. Virological failure was defined as two HIV-RNA measurements of 2000 copies/ml or greater at or after week 16 and before treatment discontinuation. METHODS: Using biological cut-offs to define resistance, assigned NRTI and randomized drug regimens, continuous and dichotomous phenotypic susceptibility scores (PSS) were calculated for each virus. Efavirenz hypersusceptibility as a dichotomous value was defined as less than 0.4-fold resistance. Associations between virological failure and continuous and dichotomous PSS were evaluated using Kaplan-Meier curves and Cox proportional hazards regression models. RESULTS: A higher baseline viral load (P < 0.02) and lower dichotomous or continuous baseline PSS (P = 0.004 and P < 0.001, respectively) were independently associated with virological failure. In the 85 subjects who received efavirenz, efavirenz hypersusceptibility (P = 0.042, hazard ratio 0.43, 95% confidence interval 0.19-0.97) was independently associated with a reduced risk of virological failure. CONCLUSION: Reduced phenotypic susceptibility was a significant independent risk factor for virological failure. The presence of efavirenz hypersusceptibility appeared to enhance virological responses during treatment with efavirenz in combination with NRTIs. The retrospective calculation of continuous PSS accurately identified treatment regimens containing sufficient drug activity to prevent virological failure.
Authors: Victoria A Johnson; Vincent Calvez; Huldrych F Günthard; Roger Paredes; Deenan Pillay; Robert Shafer; Annemarie M Wensing; Douglas D Richman Journal: Top Antivir Med Date: 2011-11
Authors: Annemarie M Wensing; Vincent Calvez; Francesca Ceccherini-Silberstein; Charlotte Charpentier; Huldrych F Günthard; Roger Paredes; Robert W Shafer; Douglas D Richman Journal: Top Antivir Med Date: 2019-09
Authors: Karen T Tashima; Katie R Mollan; Lumine Na; Rajesh T Gandhi; Karin L Klingman; Carl J Fichtenbaum; Adriana Andrade; Victoria A Johnson; Joseph J Eron; Laura Smeaton; Richard H Haubrich Journal: HIV Clin Trials Date: 2015-07-27
Authors: Lisa M Demeter; Victor DeGruttola; Stephanie Lustgarten; Daniel Bettendorf; Margaret Fischl; Susan Eshleman; William Spreen; Bach-Yen Nguyen; Christine E Koval; Joseph J Eron; Scott Hammer; Kathleen Squires Journal: HIV Clin Trials Date: 2008 Jan-Feb
Authors: N T Parkin; N S Hellmann; J M Whitcomb; L Kiss; C Chappey; C J Petropoulos Journal: Antimicrob Agents Chemother Date: 2004-02 Impact factor: 5.191
Authors: Barbara A Rath; Kaveh Pouran Yousef; David K Katzenstein; Robert W Shafer; Christof Schütte; Max von Kleist; Thomas C Merigan Journal: PLoS One Date: 2013-04-17 Impact factor: 3.240